The Poseidon Foundation Announces Fundraising Timetable Ahead of Platform Launch
The Poseidon Foundation (“Poseidon”) is pleased to announce the timetable for its year-long public fundraising phase which encompasses three token sales ahead of the platform’s official launch in August 2019. The first token sale will launch on 16th June 2018 and will last six weeks ending 29th July 2018. The second token sale will be launched on 3rd November 2018 lasting four weeks and the third token sale will launch on 4th May 2019 for two weeks.
Poseidon is a non-profit which uses blockchain technology to integrate carbon markets into transactions at the point-of-sale, giving individuals and organisations the opportunity to rebalance their climate impact by supporting forestry conservation projects around the world when they buy and sell everyday items.
During the three sales, 18 billion OCEAN tokens will be available for purchase. OCEAN is a single utility token that provides access to carbon credits through the Poseidon platform. Using OCEAN tokens, platform users will be able to offset the unavoidable climate impact of their businesses and everyday lives. During the first raise, OCEAN will be available for purchase at a 35% discount against the token’s internal value, until 29th July using Stellar Lumens, Bitcoin, and Ethereum.
The internal value of OCEAN will be derived from an external and independent benchmark of the total value of the global carbon market, which is currently estimated to be approximately €8.64 billion. 36 billion OCEAN tokens will be issued, each with a value of €0.24. Contributors to the token sale will enjoy discounts against the launch value, as outlined in the schedule below.
As a non-profit foundation, Poseidon will use 80% of the funds raised from token sale to purchase carbon credits for the platform. The remaining funds will be used to cover operational costs, including further development of the platform, R&D and the onboarding of new pilot projects with retailers. Should contributors prefer, there will be an option to make charitable donations to Poseidon. In the case of charitable donations, 100% of the funds committed will be used to purchase carbon credits and directly support forest conservation projects in the rainforest. Laszlo Giricz, founder and CEO of Poseidon, said, “The first token sale will be the culmination of months of hard work by our talented team. Our platform is the first of its kind to truly put consumers in control of their own carbon footprint when buying anything from a cup of coffee to a litre of fuel.”
“We are already operational at Ben & Jerry’s Scoop Shop in London where we have protected over 1,500 trees in just over a month. This represents a small example of the positive environmental impact the platform could deliver across multiple retailers.”
Notes to Editors
The three OCEAN token sales will be scheduled as follows:
First token sale
Second token sale
Third token sale
|Duration: 6 weeks||
Duration: 4 weeks
Duration: 2 weeks
|Start: 16 June 2018, noon GMT||
Start: 03 November 2018, noon GMT
Start: 04 May 2019, noon GMT
|End: 29 July 2018, 11:59 PM GMT||
End: 09 December 2019, 11:59 PM GMT
End: 19 May 2019, 11:59 PM GMT
|Token Discount: 35%||
Token Discount: 20%
Token Discount: 5%
|Token Price: €0.1560||
Token Price: €0.1920
Token Price: €0.2280
Poseidon is a non-profit foundation that empowers individuals to rebalance the climate impact of their lifestyle choices with a breakthrough approach. Using blockchain technology, it integrates carbon markets into everyday retail transactions at the point-of-sale and allows users to track the positive impact of their transactions on individual forest conservation projects. This will transform people’s relationship to their carbon footprint, encourage vital behavior change and unlock the considerable growth potential of carbon markets to effectively address climate change.
To find out more about Poseidon - https://poseidon.eco/
Hawthorn Advisors for Poseidon
Tel: +44 (0) 20 3745 4977
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
XINHUANET: Promotion Event of The Most Beautiful Shooting Location in China Held During Cannes Film Festival25.5.2019 18:20:00 CEST | Pressemelding
On May 16 (local time), an event was held at the 72nd Cannes Film Festival to recommend China’s most beautiful shooting locations on the theme of “Fascinating China.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190525005008/en/ The representative from Cannes Convention Bureau (1st L), Michel Chevillon (C), vice president of the French Riviera Chamber of Commerce and Industry and head of hotel association, and Adeline CHAUVEAU (3rd R), officer in charge of film and television projects from French Embassy to China, pose for a group photo with the representatives from the cities awarded for "The most beautiful shooting location in China." (Photo: Business Wire) In the event, the Yellow Sea National Forest Park in Dongtai, Jiangsu Province, the One Hundred Mile Azalea Forest in Bijie, Guizhou Province, Siming District of Xiamen, Fujian Province, and the Li Autonomous County in Lingshui, Hainan Province were on the list. The p
Knopp Biosciences Presents Positive Preclinical Data for Lead Neonatal Epilepsy Drug Candidate at 2019 Antiepileptic Drug and Device Trials XV Conference24.5.2019 14:00:00 CEST | Pressemelding
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today presented in vitro and in vivo data for the company’s lead molecule for the targeted treatment of KCNQ2-neonatal epileptic encephalopathy (KCNQ2-NEE) at the Antiepileptic Drug and Device Trials XV Conference in Miami, Florida. KCNQ2-NEE, a rare infant genetic epilepsy, results from mutations in genes encoding the Kv7.2/Kv7.3 ion channel, leading to frequent seizures and profound developmental delay. The preclinical data were presented by Steven Dworetzky, Ph.D., Knopp’s Chief Scientific Officer, a longtime Kv7 researcher who led the group that first cloned the Kv7.2 and Kv7.3 genes during his former tenure with the Bristol-Myers Squibb Co. Dr. Dworetzky presented results demonstrating the in vitro nanomolar activity of KB-3061 and its significant seizure protection in the maximal electroshock mo
Accelerate Your Business in South Korea Through 2019 K-Startup Grand Challenge24.5.2019 10:20:00 CEST | Pressemelding
Entrepreneurs from across the globe should set their sights on participating in the 2019 K-Startup Grand Challenge. Supported by the Ministry of SMEs and Startups and National IT Industry Promotion Agency (NIPA) of South Korea, the initiative provides invaluable support and comprehensive resources to early age startups. Applications for the K-Startup Grand Challenge are currently being accepted through June 14, 2019. In order to advance in the program, teams must pass a regional audition. A judging panel of startup ecosystem experts and Korean accelerators will select 40 teams to participate in an enriching 3.5 month-long acceleration program in Korea. The selected teams will have exclusive access to free office space at the Startup Campus in Pangyo Techno Valley, one-on-one mentoring, information sessions, coaching on Korean and Asian business culture and the chance to attend insightful seminars on accounting regulations to tax laws, patents and more. Opportunities for networking with
New Investigational Clinical Data for Ipsen’s Oncology Products in 11 Solid Tumor Types to Be Presented at 2019 ASCO Annual Meeting24.5.2019 05:00:00 CEST | Pressemelding
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new data from clinical studies on investigational uses of cancer medicines cabozantinib (Cabometyx®), liposomal irinotecan (Onivyde®), and lanreotide autogel (Somatuline®, marketed as Somatuline Depot® in the United States) will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting takes place in Chicago, Illinois, U.S., 31 May–4 June 2019; data featuring Ipsen medicines includes: New data from the Phase 3 CELESTIAL trial on the association of adverse events with efficacy outcomes for cabozantinib in patients with advanced hepatocellular carcinoma Overview of the Phase 3 COSMIC-312 trial of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma who have not received previous systemic anticancer therapy First Phase 2 data from the CaboGIST study (trial 1317) from the European Organization for Research and Treatment of
The Posiflex Group Showcases an Ecosystem of Connected Solution Endpoints with IoT Remote Monitoring at Computex 201924.5.2019 01:00:00 CEST | Pressemelding
For the Computex 2019 show, The Posiflex Group is featuring leading solution technology from the family of brands as a fully Serviced IoT Ecosystem. Solution end points include: Connected Modular Kiosks, POS Terminals, and Digital Signage solutions from Posiflex and KIOSK Information Systems Smart Medical Displays with gesture controls from Portwell Connected Gaming Solutions with Player Tracking Technology from Portwell subsidiary, Ganlot The booth display is based on common field service endpoints represented in a European Manor Destination Resort setting. Field solutions for an array of vertical market applications include QSR ordering, cinema ticketing, fashion retail customer loyalty, interactive signage, hotel / medical center check-in and bill pay, as well as casino gaming technology. This year, in addition to their renowned POS product suite, Posiflex will be featuring newly introduced Modular Kiosk platforms (co-designed by KIOSK and Posiflex), which are configure-to-order sta
Audi China President Thomas Owsianski to Keynote at CES Asia 201923.5.2019 20:00:00 CEST | Pressemelding
The Consumer Technology Association (CTA)TM today announced that Thomas Owsianski, president of Audi China, will deliver a keynote address at the upcoming CES Asia 2019. Now in its fifth year, CES Asia will run June 11-13, 2019 at the Shanghai New International Expo Centre (SNIEC) in Shanghai, China. Thomas Owsianski’s keynote is scheduled for 4 PM, Tuesday, June 11, where he will unveil Audi’s vision in transforming mobility from a driving experience to a digital adventure. Mr. Owsianski joined the top management team of Audi China in August 2018 and was named President in October 2018. “Audi has been at the forefront of driving global transformation in the automotive industry through their breakthrough advancements in technology,” said Karen Chupka, executive vice president, CES. “Innovation has revolutionized the transportation experience, and we welcome Mr. Owsianski to the CES Asia stage to share Audi’s vision for the future of global mobility.” Throughout Asia and beyond, technol